Journal of Ovarian Research· 2026Q1
LncRNA RBMS3-AS3 promotes ovarian cancer progression by regulating QKI and RBFOX2
- 0citations
- Q1SCImago
- 2026year
Short summary
LncRNA RBMS3-AS3 promotes ovarian cancer progression by physically binding to and stabilizing QKI and RBFOX2 proteins, thereby suppressing their ubiquitination and proteasomal degradation.
AI-generated from the title and abstract; the full text is not read.
Key points
- RBMS3-AS3 is highly expressed in ovarian cancer and linked to worse survival.
- RBMS3-AS3 promotes ovarian cancer cell proliferation, migration, and invasion.
- RBMS3-AS3 directly binds to and stabilizes QKI and RBFOX2 proteins.
- RBMS3-AS3 prevents QKI and RBFOX2 ubiquitination and proteasomal degradation.
- Co-knockdown of QKI and RBFOX2 rescues the oncogenic effects of RBMS3-AS3 overexpression.
AI-generated from the title and abstract; the full text is not read.
Abstract
Long non-coding RNAs (lncRNAs) exert pivotal regulatory functions in the malignant progression of ovarian cancer. Despite this, the biological roles and underlying molecular mechanisms of lncRNA RBMS3-AS3 in ovarian cancer pathogenesis have yet to be fully elucidated. RBMS3-AS3 is highly expressed in ovarian cancer, with its expression correlated with poor overall survival in patients. It was predominantly localized in the cytoplasm of ovarian cancer cells. Silencing of lncRNA RBMS3-AS3, RBFOX2 (RNA binding fox-1 homolog 2), or QKI (Quaking) suppressed cell proliferation, migration, and invasive capacity, whereas their overexpression enhanced these oncogenic behaviors. Bioinformatic analyses identified QKI and RBFOX2 as potential downstream targets of RBMS3-AS3, and RNA pull-down and RIP assays verified the direct interaction between RBMS3-AS3 and RBFOX2/QKI. Moreover, silencing RBMS3-AS3 accelerated proteasomal degradation of QKI and RBFOX2 proteins via enhancing their ubiquitination. Importantly, simultaneous co-knockdown of QKI and RBFOX2 rescued the oncogenic effects of RBMS3-AS3 overexpression. RBMS3-AS3 promotes ovarian cancer malignant progression by physically binding to and stabilizing the oncoproteins QKI and RBFOX2. Collectively, these findings suggest that RBMS3-AS3 may represent a promising novel therapeutic target for ovarian cancer intervention.
The authors' abstract, as published at the source. Journal of Ovarian Research, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Cancer ResearchBiochemistry, Genetics and Molecular Biology